



WOMEN CARE | CHILD CARE | FERTILITY

October 31, 2026

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai - 400051.
Symbol: RAINBOW

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001.
Scrip Code: 543524

Sub: Outcome of the Board Meeting held on October 31, 2026.

Dear Sir/ Madam,

This is to inform that pursuant to Regulations 30 and 33 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the SEBI Listing Regulations") and in furtherance of our letter dated October 23, 2026, the Board of Directors of the Company, at its meeting held today i.e., October 31, 2026, has considered and approved the following:

1. Financial Results:

The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026 ("**Financial Results**").

A copy of the signed Results along with Limited Review Report issued by the Statutory Auditors M/s. S.R. Batliboi & Associates LLP, Chartered Accountants, are enclosed as **Annexure – A**.

The Board Meeting commenced at 4:45 P.M and concluded at 5:15 P.M.

This is for your information and record.

Thanking You,

Yours Faithfully,

For **Rainbow Children's Medicare Limited**

SHREYA

MITRA

Shreya Mitra

Company Secretary and Compliance Officer

Digitally signed by
SHREYA MITRA
Date: 2026.10.31
18:37:58 +05'30'

Encl.: As above

Rainbow Children's Medicare Limited

Registered Office: 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad- 500034, Telangana

CIN:L85110TG1998PLC029914

Corporate Office: 8-2-19/1/A, Daulet Arcade, Road No. 11, Banjara Hills, Hyderabad- 500034, Telangana

info@rainbowhospitals.in

1800 2122

www.rainbowhospitals.in

OUR PRESENCE: BENGALURU | CHENNAI | DELHI | GUWAHATI | HYDERABAD | RAJAHMUNDRY | VIJAYAWADA | VISAKHAPATNAM | WARANGAL

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Rainbow Children's Medicare Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended


Review Report to
The Board of Directors
Rainbow Children's Medicare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Rainbow Children's Medicare Limited (the "Company") for the quarter ended 30 September 2026 and year to date from 1 April 2026 to 30 September 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004



per Atin Bhargava

Partner

Membership No.: 594777

UDIN: 26504777TMWEZW7974



Place: Hyderabad

Date: October 31, 2026

Rainbow Children's Medicare Limited						
CIN: L85110TG1998PLC029914						
Registered Office : 8-2-120/103/1, Survey No. 403, Road No.2, Banjara Hills, Hyderabad, Telangana-500034						
Tel: +91 40 4969 2244, e-mail : companysecretary@rainbowhospitals.in						
Statement of Unaudited Standalone Financial Results for the quarter and year to date ended 30 September 2026						
Particulars	Quarter ended			(Rs. in Million except per share data)		Year ended
	30 September 2026	30 June 2026	30 September 2025	Year to date ended		Year ended
	Unaudited	Unaudited	Unaudited	30 September 2026	30 September 2025	31 March 2026
				Unaudited	Unaudited	Audited
1. Income						
a. Revenue from operations	4,869.91	4,105.47	4,084.96	8,975.38	7,432.44	15,456.60
b. Other income	80.92	127.57	81.73	208.49	274.58	434.54
Total income	4,950.83	4,233.04	4,166.69	9,183.87	7,707.02	15,891.14
2. Expenses						
a. Cost of materials consumed	641.10	546.85	560.93	1,187.95	1,000.43	1,996.69
b. Employee benefits expense	672.36	599.08	532.74	1,271.44	1,025.10	2,123.93
c. Finance costs	199.14	192.49	173.09	391.63	347.02	713.96
d. Depreciation and amortisation expense	398.09	376.26	331.82	774.35	657.75	1,362.61
e. Professional fees to doctors	1,242.43	1,087.30	966.26	2,329.73	1,834.07	3,770.65
f. Other expenses	799.06	725.65	617.85	1,524.71	1,170.45	2,566.76
Total expenses	3,952.18	3,527.63	3,182.69	7,479.81	6,034.82	12,534.60
3. Profit before exceptional items and tax [1-2]	998.65	705.41	984.00	1,704.06	1,672.20	3,356.54
4. Exceptional items	-	-	-	-	-	15.39
5. Profit before tax [3-4]	998.65	705.41	984.00	1,704.06	1,672.20	3,341.15
6. Tax expenses						
a. Current tax	305.19	189.59	280.20	494.78	448.85	917.83
b. Deferred tax credit	(57.47)	(11.24)	(27.87)	(68.71)	(22.06)	(73.38)
c. Adjustment of tax relating to earlier periods	-	-	-	-	(3.46)	(3.46)
Total tax expense	247.72	178.35	252.33	426.07	423.33	840.99
7. Profit after tax [5-6]	750.93	527.06	731.67	1,277.99	1,248.87	2,500.16
8. Other comprehensive income						
Items that will not be reclassified subsequently to the Statement of Profit or Loss						
a. Re-measurement loss on defined benefit obligation	(2.21)	(2.21)	(0.72)	(4.42)	(1.44)	(8.83)
b. Income tax effect	0.55	0.56	0.18	1.11	0.36	2.22
Other comprehensive income (net of tax)	(1.66)	(1.65)	(0.54)	(3.31)	(1.08)	(6.61)
9. Total comprehensive income [7+8]	749.27	525.41	731.13	1,274.68	1,247.79	2,493.55
10. Paid-up equity share capital (Face value of Rs. 10 each)	1,015.66	1,015.66	1,015.59	1,015.66	1,015.59	1,015.59
11. Other equity						15,874.98
12. Earning per share (Face value of Rs.10 each)						
a. Basic (Rs)	7.41	5.20	7.20	12.61	12.30	24.62
b. Diluted (Rs)	7.41	5.20	7.20	12.61	12.30	24.62
	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	



Notes :

- 1 The above statement of unaudited standalone financial results of Rainbow Children's Medicare Limited ("the Company"), which have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 31 October 2026.
- 2 Pursuant to the resolutions passed by the Board of Directors on 9 February 2025 and by the Shareholders on 2 April 2025, the Company approved 'The Rainbow Children's Medicare Limited - Employee Stock Option Scheme 2025 ("ESOP 2025")' in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI SBEB SE Regulations"). The ESOP 2025 is for issue of employee stock options to eligible employees, which may result in an issuance of a maximum number of 1,015,000 Equity Shares. Upon exercise and payment of the exercise price, an option holder will be entitled to be allotted one equity share per employee stock option. During the six months period ended 30 September 2026, the Nomination and Remuneration Committee ("NRC") of the Company granted 58,260 Stock options under the ESOP 2025 to its eligible employees. The Exercise price per stock option has been determined at a discount of not more than 20% on the latest available closing price of the Company's equity shares on the National Stock Exchange of India Limited, as on the trading day immediately preceding the date on which the grant of options was approved by the NRC. The Stock options vest after a minimum vesting period of 1 year and not later than maximum period of 10 years from the date of grant. The vested stock options are exercisable upto 2 years from the date of each vesting. During the quarter, eligible employees have exercised 2,131 stock options at an exercise price of Rs.1,246 each.
- 3 On 29 July 2026, the Company has executed the definitive transaction documents, including a Shareholders' Agreement ("Transaction Documents"), in connection with the proposed capacity addition through development of a new children and women's hospital at Malad, Mumbai through its wholly owned subsidiary, Rainbow Women & Children's Hospital Private Limited ("RWCHPL") and diluted 24% of its stake in RWCHPL.
- 4 On 29 July 2026, the Company has executed a Partnership Interest and Contribution Transfer Agreement ("PICTA") with the existing partners of Super Prime Medical Care LLP ("LLP"), in connection with the acquisition by the Company of 64% partnership interest for an upfront cash payment of Rs. 185.10 million and an additional consideration of Rs. 13.30 million is payable which is contingent upon successful integration, bringing the total consideration to Rs. 198.40 million. Consequent to this acquisition, the Company has acquired a controlling interest in the LLP with effect from 14 August 2026 upon satisfactory completion of closing conditions under the PICTA and accordingly, the LLP has been consolidated with effect from that date. The transaction was accounted in accordance with Ind AS 103.
- 5 The Company is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operations of the Company are concentrated in India, and hence, the Company is considered to operate only in one geographical segment.
- 6 The unaudited standalone financial results for the quarter and year to date ended 30 September 2026, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.rainbowhospitals.in).

for and on behalf of the Board of Directors of
Rainbow Children's Medicare Limited



Dr. Ramesh Kancharla
Chairman and Managing Director
DIN: 00212270

Place : Hyderabad
Date : 31 October 2026

Standalone Balance Sheet

(Rs. in Million)

Particulars	As at	
	30 September 2026	31 March 2026
	Unaudited	Audited
ASSETS		
Non-current assets		
a. Property, plant and equipment	8,906.35	8,554.94
b. Capital work-in-progress	1,010.79	756.61
c. Right-of-use of assets	6,437.28	5,930.61
d. Intangible assets	85.60	94.19
e. Intangible assets under development	107.36	34.70
f. Financial assets		
(i) Investments	2,381.17	2,176.99
(ii) Loans	656.93	659.09
(iii) Other financial assets	520.23	1,415.31
g. Deferred tax assets (net)	431.37	361.54
h. Non-current tax assets (net)	170.55	136.95
i. Other non-current assets	446.70	396.75
Total non-current assets	21,154.33	20,517.68
Current assets		
a. Inventories	400.44	299.06
b. Financial assets		
(i) Investments	2,965.19	3,714.30
(ii) Trade receivables	1,253.18	1,003.50
(iii) Cash and cash equivalents	185.01	172.80
(iv) Bank balances other than (iii) above	0.32	0.05
(v) Loans	63.96	50.43
(vi) Other financial assets	1,546.09	492.77
c. Other current assets	301.58	233.29
Total current assets	6,715.77	5,966.20
TOTAL ASSETS	27,870.10	26,483.88
EQUITY AND LIABILITIES		
EQUITY		
a. Equity share capital	1,015.66	1,015.59
b. Other equity	16,384.16	15,874.98
TOTAL EQUITY	17,399.82	16,890.57
LIABILITIES		
Non-current liabilities		
a. Financial liabilities		
(i) Lease liabilities	8,400.55	7,784.34
b. Provisions	183.83	152.95
Total non-current liabilities	8,584.38	7,937.29
Current liabilities		
a. Financial liabilities		
(i) Lease liabilities	261.10	229.28
(ii) Trade payables		
a) Total outstanding dues to micro enterprises and small enterprises	113.28	253.18
b) Total outstanding dues to creditors other than micro enterprises and small enterprises	948.75	620.88
(iii) Other financial liabilities	240.44	240.78
b. Other current liabilities	264.19	263.22
c. Provisions	58.14	48.68
Total current liabilities	1,885.90	1,656.02
TOTAL EQUITY AND LIABILITIES	27,870.10	26,483.88



Standalone Statement of Cash Flows		
	(Rs. in Million)	
Particulars	For the year to date ended 30 September 2026	For the year to date ended 30 September 2025
	Unaudited	Unaudited
Cash flows from operating activities		
Profit before tax	1,704.06	1,672.20
Adjustments:		
Depreciation and amortisation expense	774.35	657.75
Gain on redemption of mutual funds (net)	(104.07)	(182.70)
Net gain on financial assets measured at fair value through profit or loss	(16.02)	(18.02)
Unrealised foreign exchange loss (net)	(1.08)	-
Interest income on financial assets carried at amortised cost	(87.10)	(61.78)
Employee share based payment expense	16.47	6.54
Finance cost	391.63	347.02
Investments written off	0.03	-
Bad debts written off	-	1.04
Reversal of impairment loss on non-current investment	(0.10)	-
Allowance / (reversal) for expected credit loss	5.36	(24.84)
Loss / (gain) on sale of property, plant and equipment (net)	0.66	(11.86)
Liabilities no longer required written back	(0.12)	-
	2,684.07	2,385.35
Adjustments for working capital:		
Increase in inventories	(101.38)	(76.84)
Increase in trade receivables	(255.04)	(268.78)
Increase in financial and other assets	(216.50)	(21.68)
Increase in trade payables	187.87	269.49
(Decrease) / increase in financial and current liabilities	(1.73)	29.23
Increase in provisions	35.93	13.83
Cash generated from operations	2,333.22	2,330.60
Income tax paid (net)	(528.38)	(415.90)
Net cash flows generated from operating activities (A)	1,804.84	1,914.70
Cash flows from investing activities		
Purchase of property, plant and equipment, intangibles, intangible assets under development including capital advances, capital creditors and capital work-in-progress	(1,230.57)	(927.37)
Proceeds from sale of property, plant and equipment	0.11	12.77
Investment in unquoted equity instruments of subsidiary companies	-	(1,548.12)
Purchase of investment in subsidiary LLP	(185.10)	-
Investment in compulsory convertible debentures of subsidiary	(40.00)	-
Redemption of unquoted equity instruments of subsidiary company	0.02	-
Investment in non convertible redeemable preference shares of subsidiary companies	-	(487.88)
Bank deposits invested with maturity of more than three months	(166.86)	(69.81)
Bank deposits redeemed with maturity of more than three months	199.42	22.91
Interest received	42.31	17.14
Gain on redemption of mutual funds (net)	104.07	182.70
Investment in mutual funds	(2,479.88)	(3,439.94)
Redemption of mutual funds	3,245.01	5,072.68
Loans given	(20.00)	(30.00)
Loans realised	20.00	2.00
Payment towards lease registration charges and upfront lease premium	(13.01)	-
Net cash flows (used in) investing activities (B)	(524.48)	(1,192.92)
Cash flows from financing activities		
Payment of principal portion of lease liabilities	(93.90)	(76.66)
Interest paid	(392.35)	(347.36)
Purchase of treasury shares	(429.01)	-
Proceeds from issuance of equity shares (including treasury shares)	2.59	0.07
Dividend paid	(355.48)	(304.65)
Net cash flows (used in) financing activities (C)	(1,268.15)	(728.60)
Net increase / (decrease) in cash and cash equivalents (A+B+C)	12.21	(6.82)
Cash and cash equivalents at the beginning of the period	172.80	168.90
Cash and cash equivalents at the end of the period (note a)	185.01	162.08
Notes:		
a) Components of cash and cash equivalents	As at 30 September 2026	As at 30 September 2025
Cash on hand	7.14	6.05
Balance with banks:		
- Current accounts	177.87	156.03
- On deposit accounts (with original maturity of 3 months or less)	-	-
	185.01	162.08

* Includes an amount of Rs. 35.23 million (30 September 2025 : Rs. Nil) earmarked towards ongoing CSR projects



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Rainbow Children's Medicare Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Rainbow Children's Medicare Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Rainbow Children's Medicare Limited (the "Holding Company"), its subsidiaries and other consolidating entity (the Holding Company, its subsidiaries and other consolidating entity together referred to as "the Group") for the quarter ended 30 September 2026 and year to date from 1 April 2026 to 30 September 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Holding Company:


Rainbow Children's Medicare Limited

Subsidiaries:

- a. Rainbow Speciality Hospitals Private Limited
- b. Rosewalk Healthcare Private Limited
- c. Rainbow C R O Private Limited
- d. Rainbow Fertility Private Limited
- e. Rainbow Children's Hospital Private Limited
- f. Rainbow Woman & Children's Hospital Private Limited
- g. Prashanthi Medicare Private Limited (with effect from 1 July 2025)
- h. Pratiksha Women & Child Care Hospital Private Limited (with effect from 18 August 2025)
- i. Super Prime Medical Care LLP (with effect from 14 August 2026)

Other Consolidating Entity:

- a. Rainbow Children's Hospital Foundation



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the unaudited interim financial results in respect of 7 subsidiaries, whose unaudited interim financial results include total assets of Rs 1,344.70 million as at 30 September 2026, total revenues of Rs 248.37 million and Rs 488.13 million, total net profit after tax of Rs 21.38 million and Rs 49.96 million, total comprehensive income of Rs 21.24 million and Rs 49.68 million, for the quarter ended 30 September 2026 and the period ended on that date respectively, and net cash outflows of Rs 18.89 million for the period from 01 April 2026 to 30 September 2026, as considered in the Statement which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the reports of the other auditors.

For S.R. Batliboi & Associates LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

Atin Bhargava
per Atin Bhargava
Partner
Membership No.: 504777




UDIN: 26504777ZSWRCm7042

Place: Hyderabad

Date: October 31, 2026

Rainbow Children's Medicare Limited						
CIN: L85110TG1998PLC029914						
Registered Office : 8-2-120/103/1, Survey No. 403, Road No.2, Banjara Hills, Hyderabad, Telangana-500034						
Tel: +91 40 4969 2244, e-mail : companysecretary@rainbowhospitals.in						
Statement of Unaudited Consolidated Financial Results for the quarter and year to date ended 30 September 2026						
Particulars	(Rs. in Million except per share data)					
	Quarter ended			Year to date ended		Year ended
	30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income						
a. Revenue from operations	5,480.23	4,699.85	4,447.99	10,180.08	7,977.28	17,030.77
b. Other income	81.26	127.10	81.95	208.36	282.11	437.88
Total income	5,561.49	4,826.95	4,529.94	10,388.44	8,259.39	17,468.65
2. Expenses						
a. Cost of materials consumed	737.70	645.42	622.14	1,383.12	1,097.12	2,270.29
b. Employee benefits expense	751.76	668.50	587.80	1,420.26	1,104.00	2,335.30
c. Finance costs	219.96	212.05	188.49	432.01	369.27	776.17
d. Depreciation and amortisation expense	446.06	421.97	358.41	868.03	700.28	1,505.70
e. Professional fees to doctors	1,402.99	1,238.19	1,063.19	2,641.18	1,980.77	4,188.10
f. Other expenses	887.98	801.29	686.21	1,689.27	1,270.51	2,795.41
Total expenses	4,446.45	3,987.42	3,506.24	8,433.87	6,521.95	13,870.97
3. Profit before exceptional items and tax [1-2]	1,115.04	839.53	1,023.70	1,954.57	1,737.44	3,597.68
4. Exceptional items	-	-	-	-	-	15.39
5. Profit before tax [3-4]	1,115.04	839.53	1,023.70	1,954.57	1,737.44	3,582.29
6. Tax expenses						
a. Current tax	332.19	222.84	292.64	555.03	467.46	964.79
b. Deferred tax credit	(56.08)	(8.71)	(25.18)	(64.79)	(20.85)	(194.48)
c. Adjustment of tax relating to earlier periods	-	-	-	-	(3.46)	(3.46)
Total tax expense	276.11	214.13	267.46	490.24	443.15	766.85
7. Profit after tax [5-6]	838.93	625.40	756.24	1,464.33	1,294.29	2,815.44
8. Other comprehensive income						
Items that will not be reclassified subsequently to the Statement of Profit or Loss						
a. Re-measurement loss on defined benefit obligation	(2.39)	(2.40)	(0.25)	(4.79)	(0.49)	(9.58)
b. Income tax effect	0.60	0.61	0.09	1.21	0.18	2.41
Other comprehensive income (net of tax)	(1.79)	(1.79)	(0.16)	(3.58)	(0.31)	(7.17)
9. Total comprehensive income [7+8]	837.14	623.61	756.08	1,460.75	1,293.98	2,808.27
Profit after tax attributable to						
Owners of the company	820.91	605.72	752.50	1,426.63	1,287.49	2,783.23
Non-controlling interests	18.02	19.68	3.74	37.70	6.80	32.21
Profit after tax	838.93	625.40	756.24	1,464.33	1,294.29	2,815.44
Other comprehensive income attributable to						
Owners of the company	(1.78)	(1.78)	(0.18)	(3.56)	(0.39)	(7.12)
Non-controlling interests	(0.01)	(0.01)	0.02	(0.02)	0.08	(0.05)
Other comprehensive income	(1.79)	(1.79)	(0.16)	(3.58)	(0.31)	(7.17)
Total comprehensive income attributable to						
Owners of the company	819.13	603.94	752.32	1,423.07	1,287.10	2,776.11
Non-controlling interests	18.01	19.67	3.76	37.68	6.88	32.16
Total comprehensive income	837.14	623.61	756.08	1,460.75	1,293.98	2,808.27
10. Paid-up equity share capital (Face value of Rs. 10 each)	1,015.66	1,015.66	1,015.59	1,015.66	1,015.59	1,015.59
11. Other equity						15,465.15
12. Earning per share (Face value of Rs.10 each)						
a. Basic (Rs)	8.10	5.97	7.41	14.07	12.68	27.41
b. Diluted (Rs)	8.10	5.97	7.41	14.07	12.68	27.41
	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	



Notes :

- 1 The above statement of unaudited consolidated financial results of Rainbow Children's Medicare Limited ("the Company"), its subsidiaries and other consolidating entity (the Company, its subsidiaries and other consolidating entity together referred to as "the Group") which have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 31 October 2026.
- 2 Pursuant to the resolutions passed by the Board of Directors on 9 February 2025 and by the Shareholders on 2 April 2025, the Company approved 'The Rainbow Children's Medicare Limited - Employee Stock Option Scheme 2025 ("ESOP 2025")' in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("SEBI SBEB SE Regulations"). The ESOP 2025 is for issue of employee stock options to eligible employees, which may result in an issuance of a maximum number of 1,015,000 Equity Shares. Upon exercise and payment of the exercise price, an option holder will be entitled to be allotted one equity share per employee stock option.
During the six months period ended 30 September 2026, the Nomination and Remuneration Committee ("NRC") of the Company granted 58,260 Stock options under the ESOP 2025 to its eligible employees. The Exercise price per stock option has been determined at a discount of not more than 20% on the latest available closing price of the Company's equity shares on the National Stock Exchange of India Limited, as on the trading day immediately preceding the date on which the grant of options was approved by the NRC. The Stock options vest after a minimum vesting period of 1 year and not later than maximum period of 10 years from the date of grant. The vested stock options are exercisable upto 2 years from the date of each vesting.
During the quarter, eligible employees have exercised 2,131 stock options at an exercise price of Rs.1,246 each.
- 3 On 29 July 2026, the Company has executed the definitive transaction documents, including a Shareholders' Agreement ("Transaction Documents"), in connection with the proposed capacity addition through development of a new children and women's hospital at Malad, Mumbai through its wholly owned subsidiary, Rainbow Women & Children's Hospital Private Limited ("RWCHPL") and diluted 24% of its stake in RWCHPL.
- 4 On 29 July 2026, the Company has executed a Partnership Interest and Contribution Transfer Agreement ("PICTA") with the existing partners of Super Prime Medical Care LLP ("LLP"), in connection with the acquisition by the Company of 64% partnership interest for an upfront cash payment of Rs. 185.10 million and an additional consideration of Rs. 13.30 million is payable which is contingent upon successful integration, bringing the total consideration to Rs. 198.40 million. Consequent to this acquisition, the Company has acquired a controlling interest in the LLP with effect from 14 August 2026 upon satisfactory completion of closing conditions under the PICTA and accordingly, the LLP has been consolidated with effect from that date. The transaction was accounted in accordance with Ind AS 103. The Group has recognised net assets (including intangibles assets other than goodwill) of Rs. 144.23 million and goodwill of Rs. 105.81 million. From the date of acquisition, the LLP has contributed revenues amounting to Rs. 28.66 million and profit amounting to Rs. 0.53 million to the Group's performance.
In the financial year ended 31 March 2026, the LLP generated Rs 94.38 million in revenue.
As at 30 September 2026, share of 36% held by the other partners is recorded under non-controlling interest of Rs. 51.93 million.
- 5 The Group is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operations of the group are concentrated in India, and hence, the group is considered to operate only in one geographical segment.
- 6 The consolidated financial results for the quarter and year to date ended 30 September 2026, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.rainbowhospitals.in).
- 7 The unaudited consolidated financial results include the financial results of Rainbow Children's Medicare Limited and the financial results of its subsidiaries, Rainbow C R O Private Limited, Rainbow Fertility Private Limited, Rainbow Women & Children's Hospital Private Limited, Rainbow Speciality Hospitals Private Limited, Rosewalk Healthcare Private Limited, Rainbow Children's Hospital Private Limited, Prashanthi Medicare Private Limited, Pratiksha Women & Child Care Hospital Private Limited, Super Prime Medical Care LLP and its other consolidating entity, Rainbow Children's Hospital Foundation.

for and on behalf of the Board of Directors of
Rainbow Children's Medicare Limited



Dr. Ramesh Kancharla

Chairman and Managing Director
DIN: 00212270

Place : Hyderabad
Date : 31 October 2026

Consolidated Balance Sheet

(Rs. in Million)

Particulars	As at	
	30 September 2026	31 March 2026
	Unaudited	Audited
ASSETS		
Non-current assets		
a. Property, plant and equipment	9,386.76	8,924.33
b. Capital work-in-progress	1,029.10	757.51
c. Right-of-use of assets	7,303.42	6,691.81
d. Goodwill	1,674.72	1,568.90
e. Other intangible assets	389.53	373.85
f. Intangible assets under development	107.36	34.70
g. Financial assets		
(i) Investments	-	0.03
(ii) Loans	263.59	275.01
(iii) Other financial assets	511.35	1,423.24
h. Deferred tax assets (net)	563.68	500.70
i. Non-current tax assets (net)	189.22	158.23
j. Other non-current assets	499.58	411.57
Total non-current assets	21,918.31	21,119.88
Current assets		
a. Inventories	536.98	416.34
b. Financial assets		
(i) Investments	3,536.12	4,044.95
(ii) Trade receivables	1,334.14	1,031.79
(iii) Cash and cash equivalents	325.50	338.94
(iv) Bank balances other than (iii) above	0.32	-
(v) Loans	40.00	40.01
(vi) Other financial assets	1,558.65	506.43
c. Other current assets	335.53	250.08
Total current assets	7,667.24	6,628.54
TOTAL ASSETS	29,585.55	27,748.42
EQUITY AND LIABILITIES		
EQUITY		
a. Equity share capital	1,015.66	1,015.59
b. Other equity	16,124.24	15,465.15
Equity attributable to owners of the Company	17,139.90	16,480.74
Non-controlling interest	218.84	155.14
TOTAL EQUITY	17,358.74	16,635.88
LIABILITIES		
Non-current liabilities		
a. Financial liabilities		
(i) Lease liabilities	9,386.29	8,653.70
(ii) Other financial liabilities	459.98	434.07
b. Provisions	195.91	159.53
Total non-current liabilities	10,042.18	9,247.30
Current liabilities		
a. Financial liabilities		
(i) Lease liabilities	295.94	256.14
(ii) Trade payables		
a) Total outstanding dues to micro enterprises and small enterprises	145.04	295.89
b) Total outstanding dues to creditors other than micro enterprises and small enterprises	1,120.68	709.79
(iii) Other financial liabilities	263.55	259.65
b. Other current liabilities	281.85	284.14
c. Provisions	60.67	51.21
d. Deferred tax liabilities (net)	15.34	7.92
e. Current tax liabilities (net)	1.56	0.50
Total current liabilities	2,184.63	1,865.24
TOTAL EQUITY AND LIABILITIES	29,585.55	27,748.42



Consolidated Statement of Cash Flows		
	(Rs. in Million)	
Particulars	For the year to date ended 30 September 2026	For the year to date ended 30 September 2025
	Unaudited	Unaudited
Cash flows from operating activities		
Profit before tax	1,954.57	1,737.44
Adjustments:		
Depreciation and amortisation expense	868.03	700.28
Gain on redemption of mutual funds (net)	(117.27)	(190.41)
Unrealised foreign exchange loss (net)	(1.08)	-
Net gain on financial assets measured at fair value through profit or loss	(18.11)	(18.02)
Interest income on financial assets carried at amortised cost	(71.75)	(59.59)
Finance cost	432.01	369.27
Employee share based payment expense	16.47	6.54
Investments written off	0.03	-
Allowance / (reversal) for expected credit loss	8.77	(21.44)
Bad debts written off	0.15	1.42
Loss / (gain) on sale of property, plant & equipment (net)	0.66	(11.86)
Liabilities no longer required written back	(0.12)	(2.01)
	3,072.36	2,511.62
Adjustments for working capital:		
Increase in inventories	(120.64)	(127.73)
Increase trade receivables	(311.27)	(280.27)
Increase in financial and other assets	(233.24)	(41.51)
Increase in trade payables	262.88	383.13
Increase in financial and current liabilities	51.49	54.81
Increase in provisions	41.05	16.88
Cash generated from operations	2,762.63	2,516.93
Income tax paid, net	(584.95)	(441.06)
Net cash flows generated from operating activities (A)	2,177.68	2,075.87
Cash flows from investing activities		
Purchase of property, plant and equipment, other intangibles, intangible assets under development including capital advances, capital creditors and capital work-in-progress	(1,381.70)	(3,022.72)
Proceeds from sale of property, plant and equipment	0.11	12.77
Purchase of investment in subsidiary LLP, net of cash and cash equivalents acquired	(183.27)	-
Bank deposits invested with maturity of more than three months	(169.87)	(2,508.78)
Bank deposits redeemed with maturity of more than three months	203.80	2,489.94
Interest received	25.26	20.29
Gain on redemption of mutual funds (net)	117.27	190.41
Investment in mutual funds	(2,729.95)	(3,499.94)
Redemption of mutual funds	3,256.89	5,069.97
Loans realised	5.00	-
Payment towards lease registration charges and upfront lease premium	(13.01)	-
Net cash flows used in investing activities (B)	(869.47)	(1,248.06)
Cash flows from financing activities		
Payment of principal portion of lease liabilities	(107.75)	(88.00)
Interest paid	(432.02)	(369.62)
Purchase of treasury shares	(429.01)	-
Proceeds from partial disposal of investment in subsidiary without loss of control	0.02	-
Proceeds from issuance of equity shares (including treasury shares)	2.59	0.07
Dividend paid	(355.48)	(304.64)
Net cash flows used in financing activities (C)	(1,321.65)	(762.19)
Net (decrease) / increase in cash and cash equivalents (A+B+C)	(13.44)	65.62
Cash and cash equivalents at the beginning of the period	338.94	202.55
Cash and cash equivalents at the end of the period (note a)	325.50	268.17
Notes:		
a) Components of cash and cash equivalents	As at 30 September 2026	As at 30 September 2025
Cash on hand	11.02	10.60
Balance with banks:		
- Current accounts*	314.48	257.57
- On deposit accounts (with original maturity of 3 months or less)	-	-
	325.50	268.17

* Includes an amount of Rs. 36.73 million (30 September 2025 : Rs. Nil) earmarked towards ongoing CSR projects

